Showing 971-980 of 1017 results for "".
- Acne Scars: Survey Highlights the Negative Ways Acne and Acne Scars Can Affect Confidencehttps://practicaldermatology.com/news/acne-scars-survey-highlights-the-negative-ways-acne-and-acne-scars-can-affect-quality-of-life/2458539/Ninety-nine percent people would have more confidence if their acne and acne scars were gone, according to a new survey for Suneva Medical. When it comes to skin issues, respondents feel that acne scars are worse than having acne, eczema or rosacea. Nearly half of adults still have
- Valeant Dermatology Launches Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/valeant-dermatology-launches-aspire-higher-scholarship-program/2458676/Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC, launched Valeant Dermatology ASPIRE HIGHER Scholarship Program that will award scholarships of up to $10,000 each to nine individual students who will be attending an undergraduate or graduate education program during t
- NOVAN: First Patient Dosed in Phase 3 Program for SB204https://practicaldermatology.com/news/novan-first-patient-dosed-in-phase-3-program-for-sb204/2458688/The first patient has been dosed in a Phase 3 study of Novan’s investigational topical nitric oxide acne gel, Novan, Inc. reports. Novan is running two identically designed Phase 3 pivotal trials in parallel to evaluate the effic
- Bristol-Myers Squibb's Opdivo + Yervoy Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Statushttps://practicaldermatology.com/news/bristol-myers-squibbs-opdivo-yervoy-regimen-receives-expanded-fda-approval-in-unresectable-or-metastatic-melanoma-across-braf-status/2458732/The FDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma. This indication is
- U.S. Cosmetics Survey: The Millennials Lead the Packhttps://practicaldermatology.com/news/us-cosmetics-survey-the-millennials-lead-the-pack/2458733/Once again, it’s all about the millennials! Fresh off the heels of the American Academy of Facial Plastic and Reconstructive Surgery’s annual survey that showed an uptick in the number of millennials seeking nips and tucks, new research finds that millennial women are the heav
- Agents for Advanced Melanoma Among Prix Galien USA 2015 Award Recipientshttps://practicaldermatology.com/news/agents-for-melanoma-among-prix-galien-usa-2015-award-recipients/2458832/The Prix Galien USA 2015 Awards have been bestowed on Imbruvica® (ibrutinib) for best pharmaceutical agent, Opdivo® (nivolumab) and Keytruda® (pembrolizumab) for best biotechnology product, and the T2Candida Panel for best medical technology. 
- Phase 2 Psoriasis Study Shows Positive Results for Boehringer Ingelheim's Investigational Biologichttps://practicaldermatology.com/news/phase-2-psoriasis-study-shows-positive-results-for-boehringer-ingelheims-investigational-biologic/2458837/Results from a Phase II head-to-head psoriasis study show superior efficacy of Boehringer Ingelheim’s investigational biologic compound BI 655066 over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained PASI 90 with BI 655066, compared
- Novan's SB204 Demonstrates Positive Phase 2b Clinical Trial Results for the Treatment of Acne Vulgarishttps://practicaldermatology.com/news/novans-sb204-demonstrates-positive-phase-2b-clinical-trial-results-for-the-treatment-of-acne-vulgaris/2458863/Novan Therapeutics topical nitric oxide drug candidate SB204 for the treatment of acne vulgaris, demonstrated statistically significant reductions in the percent change of non-inflammatory (white heads and black heads) and
- Nerium International Announces Exclusive Usage of Anti-Aging Ingredient SIG-1273https://practicaldermatology.com/news/nerium-international-announces-exclusive-usage-of-anti-aging-ingredient-sig-1273/2458970/Nerium International added new ingredient, SIG-1273®, to the Optimera Formula of its Age-Defying Night and Day Creams. Engineered by Princeton University biochemist, Jeffry Stock, SIG-1273 is the result of 20 years of intensive biomedical skincare research, accordi
- Novan Secures $50 Million Private Financinghttps://practicaldermatology.com/news/novan-secures-50-million-private-financing/2458973/Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that it has secured $50 million in an oversubscribed private financing. New investor Malin Corporation Plc. (MLC: ISE) functioned as the cornerston